Downregulation of EphA5 by promoter methylation in human prostate cancer

详细信息    查看全文

• 作者：Shibao Li ; Yingfeng Zhu ; Chunguang Ma ; Zhenhua Qiu ; Xinju Zhang ; Zhihua Kang…
• 关键词：DNA methylation ; EphA5 receptor ; Gleason score ; Prostate cancer ; TNM staging
• 刊名：BMC Cancer
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：15
• 期：1
• 全文大小：1,810 KB
• 参考文献：1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-17. CrossRef
  2. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133-5. CrossRef
  3. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet. 2003;361:955-4. CrossRef
  4. Rodrigues DN, Butler LM, Estelles DL, de Bono JS. Molecular Pathology and Prostate Cancer Therapeutics: From Biology to Bedside. J Pathol. 2014;232:178-4. CrossRef
  5. Pasquale EB. The Eph family of receptors. Curr Opin Cell Biol. 1997;9:608-5. CrossRef
  6. Committee EN. Unified nomenclature for Eph family receptors and their ligands, the ephrins. Cell. 1997;90:403-. CrossRef
  7. Pasquale EB. Eph receptor signaling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol. 2005;6:462-5. CrossRef
  8. Kuang SQ, Bai H, Fang ZH, Lopez G, Yang H, Tong W. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood. 2010;115:2412-. CrossRef
  9. Guan M, Xu C, Zhang F, Ye C. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int J Cancer. 2009;124:88-4. CrossRef
  10. Kober P, Bujko M, Ol?dzki J, Tysarowski A, Siedlecki JA. Methyl-CpG binding column-based identification of nine genes hypermethylated in colorectal cancer. Mol Carcinog. 2011;50:846-6. CrossRef
  11. Wang J, Kataoka H, Suzuki M, Sato N, Nakamura R, Tao H, et al. Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene. 2005;24:5637-7. CrossRef
  12. Wang J, Li G, Ma H, Bao Y, Wang X, Zhou H, et al. Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma. Hum Pathol. 2007;38:1649-6. CrossRef
  13. Davalos V, Dopeso H, Casta?o J, Wilson AJ, Vilardell F, Romero-Gimenez J, et al. EPHB4 and survival of colorectal cancer patients. Cancer Res. 2006;66:8943-. CrossRef
  14. Petkova TD, Seigel GM, Otteson DC. A role for DNA methylation in regulation of EphA5 receptor expression in the mouse retina. Vision Res. 2011;51:260-. CrossRef
  15. Fu DY, Wang ZM, Wang BL, Chen L, Yang WT, Shen ZZ, et al. Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer. Hum Pathol. 2010;41:48-8. CrossRef
  16. Ross AE, Marchionni L, Vuica-Ross M, Cheadle C, Fan J, Berman DM, et al. Gene expression pathways of high grade localized prostate cancer. Prostate. 2011;71:1568-8.
  17. Cooper MA, Crockett DP, Nowakowski RS, Gale NW, Zhou R. Distribution of EphA5 receptor protein in the developing and adult mouse nervous system. J Comp Neurol. 2009;514:310-8. CrossRef
  18. Washburn CP, Cooper MA, Zhou R. Expression of the tyrosine kinase receptor EphA5 and its ligand ephrin-A5 during mouse spinal cord development. Neurosci Bull. 20
• 作者单位：Shibao Li (1)
  Yingfeng Zhu (2)
  Chunguang Ma (3)
  Zhenhua Qiu (4)
  Xinju Zhang (5)
  Zhihua Kang (1) (5)
  Zhiyuan Wu (1) (5)
  Hua Wang (1) (5)
  Xiao Xu (5)
  Hu Zhang (6)
  Guoqiang Ren (2)
  Jianmin Tang (2)
  Xiangyu Li (1)
  Ming Guan (1) (5)
  
  1. Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical School, Fudan University, 12 Central Urumqi Road, Shanghai, 200040, China
  2. Department of Pathology, Huashan Hospital North, Fudan University, Shanghai, China
  3. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
  4. Department of Laboratory Medicine, The people’s hospital of GaoZhou, GaoZhou, China
  5. Central Laboratory, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China
  6. Department of Urology, Huashan Hospital, Fudan University, Shanghai, China
  
• 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2407

文摘

Background EphA5 is a member of the Eph/ephrin family and plays a critical role in the regulation of carcinogenesis. A significant reduction of EphA5 transcripts in high-grade prostate cancer tissue was shown using a transcriptomic analysis, compared to the low-grade prostate cancer tissue. As less is known about the mechanism of EphA5 downregulation and the function of EphA5, here we investigated the expression and an epigenetic change of EphA5 in prostate cancer and determined if these findings were correlated with clinicopathologic characteristics of prostate cancer. Methods Seven prostate cell lines (RWPE-1, LNCap, LNCap-LN3, CWR22rv-1, PC-3, PC-3M-LN4, and DU145), thirty-nine BPH, twenty-two primary prostate carcinomas, twenty-three paired noncancerous and cancerous prostate tissues were examined via qRT-PCR, methylation-specific PCR, bisulfite sequencing, immunohistochemistry and western blotting. The role of EphA5 in prostate cancer cell migration and invasion was examined by wound healing and transwell assay. Results Downregulation or loss of EphA5 mRNA or protein expression was detected in 28 of 45 (62.2%) prostate carcinomas, 2 of 39 (5.1%) hyperplasias, and all 6 prostate cancer cell lines. Methylation of the EphA5 promoter region was present in 32 of 45 (71.1%) carcinoma samples, 3 of 39 (7.7%) hyperplasias, and the 6 prostate cancer cell lines. Among 23 paired prostate carcinoma tissues, 16 tumor samples exhibited the hypermethylation of EphA5, and 15 of these 16 specimens (93.8%) shown the downregulation of EphA5 expression than that of their respectively matched noncancerous samples. Immunostaining analysis demonstrated that the EphA5 protein was absent or down-regulated in 10 of 13 (76.9%) available carcinoma samples, and 8 of these 10 samples (80.0%) exhibited hypermethylation. The frequency of EphA5 methylation was higher in cancer patients with an elevated Gleason score or T3-T4 staging. Following the treatment of 6 prostate cancer cell lines with 5-aza-2-deoxycytidine, the levels of EphA5 mRNA were significantly increased. Prostate cancer cells invasion and migration were significantly suppressed by ectopic expression of EphA5 in vitro. Conclusion Our study provides evidence that EphA5 is a potential target for epigenetic silencing in primary prostate cancer and is a potentially valuable prognosis predictor and thereapeutic marker for prostate cancer.